Genmab's dispute with its business partner over blockbuster drug Darzalex, the Johnson & Johnson-owned Janssen Biotech, may draw out.
"We can say very little. The timing is naturally uncertain, but you're summarizing it quite well. Yes, it may be decided in 2021, but it potentially could be in 2022," said Genmab CEO Jan van de Winkel on Wednesday at a teleconference.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.